CHI3L1 and ovarian benign neoplasm: Kahramanoğlu et al. (2018) suggest that preoperative serum levels of CHI3L1 in patients with serous EOC were significantly higher than those with benign ovarian tumors. This finding suggests that CHI3L1 may serve as a better predictor of ovarian cancer compared to MUC16, with moderate-to-high sensitivity (80%) and specificity (70%) when a specific cutoff level is applied (Kahramanoğlu et al., 2018; Deveci et al., 2019).